|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

* Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania, USA; and
Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA
1Correspondence: The Wistar Institute, 3601 Spruce St., Philadelphia, PA 19104, USA. E-mail: herlynm{at}wistar.org
ABSTRACT
The requirement for Notch signaling in vasculogenesis and angiogenesis is well documented. In a previous study, we showed that activation of the Notch pathway in endothelial cells induces differentiation-associated growth arrest; however, the underlying mechanism remains to be elucidated. Here, we show that activation of the Notch pathway by either stimulation of cell surface Notch receptors with crosslinked soluble Delta-like 4 (sDll4)/Jagged1 (sJag1) or constitutive expression of the Notch1 intracellular domain (NIC) suppresses endothelial cell proliferation. This suppression is mediated by the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt pathways. Following Notch1 activation, both pathways were suppressed in endothelial cells, and alterations in MAPK or PI3K/Akt pathway activity reversed Notch1-induced growth inhibition. Furthermore, we found the effect of Notch1 on endothelial cells to require Mastermind-like (MAML). Overexpression of a dominant-negative mutant of MAML1 antagonized the effects of activated Notch1 on the MAPK and PI3K/Akt pathways. Ectopic expression of Hairy/Enhancer of Split 1 (HES1) consistently reproduced the inhibitory effect of NIC on endothelial cell proliferation. Together, our data demonstrate that the Notch/MAML-HES signaling cascade can regulate both MAPK and PI3K/Akt pathways, which suggests a molecular mechanism for the inhibitory effect of Notch signaling on endothelial cell proliferation.Liu Z.-J., Xiao M., Balint K., Soma A., Pinnix C. C., Capobianco A. J., Velazquez O. C., Herlyn M. Inhibition of endothelial cell proliferation by Notch1 signaling is medicated by repressing MAPK and PI3K/Akt pathways and rquires MAML1.
Key Words: cell growth cell signaling angiogensis
THE NOTCH-SIGNALING pathway is involved in development and tissue homeostasis (1)
. The central components of the Notch pathway are evolutionarily conserved. In mammals, the Notch family consists of four transmembrane receptors (Notch1Notch4) and five ligands (Jagged1, Jagged2, Delta-like (Dll) 1, Dll3, and Dll4). Binding of a ligand to its cognate receptor initiates metalloprotease- and
-secretasemediated proteolysis, which cleaves Notch and releases its intracellular domain (NIC) from the plasma membrane. Once released, NIC translocates into the nucleus and associates with transcription factors CSL [CBF1, Su(H), Lag-1] and MAML to form a heteromeric complex that mediates the transcription of target genes such as HRT, HEY, or HESRmembers of the HES and Hairy-related families of basic helix-loop-helix transcription factors (2)
. MAML functions as a critical transcriptional coactivator for Notch signaling. Three MAML family members (MAML1MAML3) have been identified in mammals (3)
and found to have non-overlapping tissue distributions. It remains unknown whether MAML gene family members have distinct functions. The N-terminal basic domain of MAML associates with the ankyrin repeat of the Notch receptor and its central and C-terminal domains have transactivation activity. The central MAML activation domain (TAD1) recruits CBP/p300 to promote nucleosome acetylation at Notch enhancers, whereas a glutamine-rich region of MAML (TAD2) enhances phosphorylation of NIC (4)
.
The involvement of Notch in regulating vascular formation has been suggested from observations of Notch/ligand expression in vascular endothelium and from defects in the vascular phenotypes of targeted mutants in the Notch pathway. Notch1, Jagged1, Jagged2, and Dll1 are expressed in vascular endothelium in vertebrates (5
6
7
8)
, whereas Notch4 is specifically restricted to the vascular endothelium (9)
. Dll4, a newly identified ligand responsible for activating Notch1 and Notch4, is preferentially expressed in arterial endothelium (10)
, which suggests a potential role for Dll4 in modulating arterial development (arteriogenesis). Targeted Notch1/, Notch1//Notch4/, Jagged1/, and Dll1/ mutants all result in vascular defects (11
12
13
14
15)
. Endothelium-specific deletion of Notch1 using Tie2-Cre and Notchflox/flox mice further confirms the essential role of Notch1 in vascular development (16)
. In addition, the human degenerative vascular disease cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) has been associated with mutations in Notch3 (17)
. The effect of Notch signaling is dose-dependent; therefore, Notch signaling must be appropriately regulated in order to maintain normal vascular development. Overactivation of the Notch pathway does affect the biological readout, as exemplified by the vascular patterning defects in mouse embryonic endothelium caused by expression of activated Notch4 (18)
. In zebrafish, development of the aorta requires the gridlock gene, a homologue of mammalian HES (19)
. Moreover, essential roles have been documented for Jagged1 and HEY1 in modulating vessel formation in vitro (20
, 21)
.
The precise mechanisms by which Notch signaling regulates vascular function remain poorly understood. Notch signaling likely exerts its effects on the vasculature in a spatiotemporal manner by influencing endothelial cell fate, such as proliferation, differentiation, and apoptosis. The effects of Notch signaling on cell fate determination usually depend on timing, gene dosage, and cell type/context. We and others have documented the regulation of endothelial cell proliferation and apoptosis by Notch signaling (21
, 22)
. To elucidate the underlying mechanism, we tested the hypothesis that Notch signaling affects endothelial cell proliferation by controlling the MAPK and PI3K/Akt signaling pathways. Both pathways are widely known to govern cell proliferation and survival. Our results show that the effects of Notch signaling on inhibiting endothelial cell proliferation are mediated through the MAPK and PI3K/Akt signaling pathways and that these activities depend on MAML1-mediated transcription of target genes. Thus, we establish a functional link between the Notch pathway and that of MAPK and PI3K/Akt and provide a better understanding of the mechanisms for Notch signaling in suppressing endothelial cell proliferation.
MATERIALS AND METHODS
Reagents
SDS-polyacrylamide gels were purchased from Invitrogen (Carlsbad, CA), h-vascular endothelial growth factor165 (VEGF) from NCI-FCRDC (Frederick, MD), and the MTT cell proliferation assay kit was from American Type Culture Collection (ATCC, Manassas, VA). Protein A-SepharoseTM was purchased from Pharmacia (New York, NY). All other chemicals and solutions were purchased from Sigma (St. Louis, MO) unless otherwise indicated.
Cells and cell culture
Human microvascular endothelial cells (HMVECs) were cultured on plates coated with type I collagen in endothelial cell medium (EGMTM) as described (23)
. Human iliac artery endothelial cells (HIAECs) were obtained from ATCC (CRL-2475) and cultured on plates coated with 1% gelatin in Medium 199 (Invitrogen) supplemented with 10% FBS (Hyclone, Logan, UT), 10 mM L-glutamine, 100 µg/ml heparin, and endothelial cell growth supplement (ECGS kindly provided by E. Levine, The Wistar Institute, Philadelphia, PA). All endothelial cells were used between passages 6 and 20. COS-7, 293 T, and NIH/3T3 cells were cultured in Dulbeccos Modified Eagles Medium (DMEM, Invitrogen) supplemented with 10% FBS. All cells were incubated at 37°C in 98% humidified air containing 5% CO2.
Construction, expression, purification, and concentration of chimeric soluble proteins
A chimeric gene encoding a fusion protein (sDll4) of the extracellular portion of human Dll4 and the Fc portion of human IgG1 was constructed as follows: The cDNA fragment of the extracellular portion of Dll4 was generated by polymerase chain reaction (PCR) using sense [5'-TAGGATCCATGGCGGCAGCGTCCCGGAGC-3'] and antisense [5'-TACCCGGGCGGCAAGCCCACGGGGAAC-3'] primers in which BamHI and SmaI sites (underlined) were created at the ends of the cDNA fragment. Dll4/pcDNA3 (kindly provided by S. Kusano, the University of North Carolina, Chapel Hill, NC) was used as template for PCR. Amplified PCR fragment was purified and subcloned into pCR2.1, which has BamHI and SmaI sites. The generated plasmid was termed Ex-Dll4/pCR2.1. The gene for the Fc portion of human IgG1 was prepared by digesting the mFas-Fc plasmid (24)
with PstI, from which a 5.8 kb fragment was recovered. After blunting and subsequent digesting with NotI, the fragment was ligated with Ex-Dll4/pCR2.1, which was then digested with SmaI and NotI, to generate sDll4-Fc/pCR2.1. The desired plasmid was confirmed by DNA sequencing. To construct sDll4/Ad5, the gene fragment of sDll4-Fc was digested with BamHI and NotI and subcloned into a BglII- and NotI- digested pShuttle-cytomegalovirus (CMV) vector. After BglII digestion, the cDNA end becomes compatible with that after BamHI digestion. Recombinant adenoviruses were generated by homologous recombination (25)
. COS-7 cells were infected with sDll4/Ad, sDll4 was purified from the culture supernatant by a protein-A-Sepharose column, and fractions containing high concentrations of sDll4 were collected and dialyzed. To generate sJag1 and sPTPBR7, the plasmids of sJag1 (a gift from T. Kadesch, University of Pennsylvania, Philadelphia, PA) and sPTPBR7 (26)
were transfected into COS-7 cells in a 100 mm tissue culture dish by calcium phosphate methods. After overnight culture in 10 ml of complete DMEM, the culture medium was replaced with 8 ml of serum-free DMEM and incubated for an additional 5 d. The culture supernatant was collected and concentrated by Amicon Ultra centrifuge filtration (NMWL, 10 kDa, Millipore, Billerica, MA). Expression of sPTPBR7 was confirmed by immunoblotting. To stimulate the Notch1 receptor more efficiently, we crosslinked soluble ligands with anti-IgG. For MTT assay, we first coated 96-well plates with anti-human IgG antibody (Ab) (10 µg/well), then washed with 100 µl/well of PBS 3 times, purified sDll4 (20 µg/well), or equal volumes (50 µl/well) of concentrated supernatant containing sJag1 or sPTPBR7 were added and plates were incubated at 37°C for 30 min. After washing well with PBS 3 times, 3000 cells/well were seeded on plates in complete M199 medium and cultured for 2 d until MTT assays were performed.
Recombinant lentiviruses, retroviruses, and adenoviruses
For gene transfer, we constructed a variety of viral vectors. GFP/lenti [pHX(prime)-CMV-GFP] was obtained from the Gene Therapy Program (Division of Medical Genetics, University of Pennsylvania, Philadelphia, PA). Into this vector, the enhanced GFP gene was inserted downstream of the CMV promoter and upstream of the post-transcriptional regulatory element of woodchuck hepatitis virus (WP) and flanked by HIV long terminal repeats (LTRs) (27)
. To construct NIC-GFP/lenti [pHX(prime)-CMV-NIC-IRES-GFP], a gene fragment encoding NIC (28)
was inserted into pIRES2-enhanced GFP (Clontech, Palo Alto, CA) between EcoRI and BamHI sites. The NIC-IRES-GFP gene fragment was then digested out with XhoI and DraI and blunted. The GFP gene in the pHX'-CMV-GFP vector was replaced by the NIC-IRES-GFP gene fragment. To achieve this, the pHX'-CMV-GFP vector was digested with NotI and BamHI. After removing a small fragment containing the GFP gene, we ligated the remaining 2 fragments with a linker [5'-GGCCGCCCGGG-3' annealed with 5'-GATCCCCGGGC-3']) to generate a SmaI site between NotI and BamHI sites. The blunted NIC-IRES-GFP gene fragment was subsequently ligated into the modified pHX'-CMV backbone vector by digesting the SmaI site. Orientation of the inserted gene fragment was confirmed by restriction digestion. The NIC-GFP/lentiviral vector was confirmed by DNA sequencing.
Production of pseudotyped lentiviruses was achieved by cotransfecting 293T cells with 3 plasmids (27)
: a packaging-defective helper construct, pCMV
R8.2 (Gene Therapy Program), which encodes the HIV-1 gag and pol precursors as well as the regulatory protein Rev; a plasmid, pMD.G (Gene Therapy Program), which codes for a vesicular stomatitis virus glycoprotein (VSV-G) envelope; and a vector construct, pHX'-CMV, which harbors the gene of interest. Briefly, 48 h after transient transfection of 293T cells via calcium phosphate method, viral supernatants were collected, filtered through 0.45 µm low-proteinbinding filters (Nalgene, Rochester, NY), and stored in aliquots at 70°C. Titers were determined by transducing NIH/3T3 cells and counting the number of green cells using fluorescence microscopy. Lentiviruses collected 48 h posttransfection displayed titers of around 107 transducing units/ml in NIH/3T3 cells.
Retroviral vector MAML305/pBabe (DN-MAML1) and empty pBabe vector (control) were described previously (29)
. H-RasV12/pBabe-puro and hemagglutinin (HA)-tagged B-RafV600E/pBabe were kindly provided by D. Tuveson (University of Pennsylvania, Philadelphia, PA) and G. Robertson (Penn State College of Medicine, Hershey, PA), respectively. Recombinant retroviruses were generated by transfecting vector into Phoenix (AMPHO) helper-free retrovirus producer lines, obtained from G. P. Nalon (Stanford University, Stanford, CA) via calcium phosphate method. Forty-eight hours after transient transfection, viral supernatants were collected, filtered, and titered. In general, retroviruses displayed titers of around 107 transducing units/ml in NIH/3T3 cells.
For recombinant adenoviruses, Notch1/Ad5 was constructed by insertion of full-length of Notch1 gene (provided by T. Kadesch, University of Pennsylvania) into adenoviral vector and confirmed by DNA sequencing. GFP/Ad5 was obtained from the Gene Therapy Program. DN-p85/Ad5 and Myr-Akt/Ad5 were provided by W. Ogawa (Kobe University, Kobe, Japan) and described elsewhere (30
, 31)
. The HES1/Ad5 (32)
was kindly provided by D. W. Ball (Johns Hopkins University School of Medicine, Baltimore, MD), and the sDll4/Ad5 was constructed as described above. All recombinant adenoviruses were propagated in 293 cells and purified using cesium chloride as described (33)
. Before infection of endothelial cells, adenoviruses were titrated to determine plaque-forming units (pfu) as described (34)
.
Viral infection of experimental cells
To infect cells with lentiviruses or retroviruses, we exposed them overnight to viruses at a multiplicity of infection (MOI) ranging from 2 to 5 in the presence of 4 µg/ml polybrene. Cells were then washed, cultured with complete medium for 2 additional days, and analyzed for protein expression by Western blot. Cells were pooled and used for subsequent assays. In general, transfection efficiency was higher than 95% with lentiviruses and 90% with retroviruses. For most cells, long-term (more than 3 mo) gene expression could be maintained. For infection of cells with adenovirus, subconfluent endothelial cells were infected with viruses for 2 h at 37°C in serum-free medium. Viral suspensions were then replaced by regular medium. After 48 h, cells were harvested for subsequent analysis as indicated in individual experiments.
Cell proliferation assays
Cell proliferation was measured by MTT cell proliferation assay according to the manufacturers protocol. Briefly, cells were seeded into 96-well plates at 3000 cells per well. On the day of harvest, 100 µl of spent medium was replaced with an equal volume of fresh medium containing 10 µl of MTT reagent. Plates were incubated at 37°C for 4 h, 100 µl of detergent reagent was added to each well, and plates were further incubated at room temperature in the dark for 2 h. Absorbance was measured at 570 nm.
Matrigel network formation assay
Wells of 24-well plates were coated with 400 µl Matrigel® (growth factor reduced, Becton Dickinson, Frankin Lakes, NJ), diluted at 1:1 with Medium199, and allowed to polymerize at 37°C for 30 min. Cells were seeded onto Matrigel at 1 x 106 cells/well with Medium199 and incubated at 37°C. Networks were observed under an inverted phase-contrast microscope and photographed at various times.
Immunoblotting
Western blots were performed as described (35)
. Membranes were probed with antibodies to: phospho-MAPK (#9106, New England Biolabs, Beverly, MA), p44/42 MAPK (#9102, New England Biolabs), Akt (#9272, New England Biolabs), phospho-Akt (Ser-473/Thr308, #9916, New England Biolabs), Dll4 (sc-18639, Santa Cruz Biotechnology, Santa Cruz, CA), Notch1 (925, a rabbit polyclonal antiserum against residues 17592095) (36)
, activated Notch1 (ab8925, Abcam, Cambridge, MA), HES1 (kindly provided by T. Sudo, Toray Industries, Inc., Kamakura, Japan), Myc-Tag 9B11 (New England Biolabs), and ß-actin (AC-15, Sigma), followed by HRP-conjugated secondary Ab (Jackson ImmunoResearch, West Grove, PA) and subjected to enhanced chemiluminescence (ECL) (Amersham). Membranes were stripped and reblotted as required in the individual experiment. For quantization, X-ray films were scanned with densitometer. The relative index was referred to a ratio of the scores of the specific bands measured by densitometry with regard to the score of the background in the same X-ray film.
RESULTS
Activation of Notch1 pathway suppresses endothelial cell proliferation
We have previously documented that enforced activation of Notch1 signaling by transient expression of NIC induces cell growth arrest of HIAECs (28)
. To study whether stimulation of Notch1 receptors on the cell surface results in cell proliferation inhibition of HIAECs, we tested two soluble forms of the Notch1 ligands, sDll4 and sJag1, for their effects on cell proliferation. We constructed sDll4 as a chimeric fusion gene, in which the cDNA encoding the extracellular domain was fused to hinge, CH2 and CH3 regions of the human IgG1 heavy-chain gene. Expression of sDll4 protein in the supernatant of recombinant adenovirus-infected COS-7 cells was confirmed by immunoprecipitation with protein A-Sepharose beads and subsequent immunoblotting with both anti-IgG and anti-Dll4 antibodies (Fig. 1
AB). sPTPBR7 (26)
was used as a control. To confirm the biological effect of sDll4 on the activation of cell surface Notch1, we stimulated HIAECs, which were transfected with Notch1/Ad for overexpression of Notch1 by sDll4 or sPTPBR7, respectively, and crosslinked with anti-IgG Ab. As showed in Fig. 1C
, crosslinked sDll4 induced activation of Notch1. Characterization of sJag1 was carried out in melanoma cells (WM9 and WM793) and Trail-Fc (a gift from T. Kadesch, University of Pennsylvania) was used as control (Fig. 1D
). The effects of sDll4 and sJag1 on HIAEC proliferation were examined by MTT assay. Treatment cells with concentrated sDll4 or sJag1 weakly but significantly inhibited cell proliferation rates (
1518%) compared with treated or untreated with controls. This finding implies a suppressive effect of activated Notch1 signaling on HIAEC proliferation (Fig. 1E
). The weak inhibitory effect could reflect the physiological concentration of endogenous Notch1 signaling strength. To determine whether sustained activation of the Notch1 pathway achieves a similar effect, we constructed a lentiviral vector encoding the NIC gene linked to the GFP marker via an internal ribosome entry site (Fig. 2
A). COS-7 cells infected with NIC-GFP/lentivirus or GFP/lentivirus (control) confirmed NIC expression (Fig. 2B
), demonstrating that GFP is a reliable marker for NIC expression in NIC-GFP/lentiviral vectortransfected cells. When HIAECs were transfected at an MOI of 5, greater than 95% of transfected cells exhibited GFP expression (Fig. 2C
) and expression was stable for greater than 6 mo. GFP-transfected cells proliferated the same as nontransfected parental cells. Similar results were obtained with HMVECs. Experiments were performed using pools from each transfected cell line in which the GFP-positive population accounted for >95% of total cells. For transfected endothelial cells, only low passage numbers (<10 after transfection) were used.
|
|
We tested the proliferative properties of transfected cells using MTT assays. Proliferation rates of HIAEC-NIC and HMVEC-NIC cells markedly decreased compared with the rates of either parental or control cells, HIAEC-GFP, and HMVEC-GFP (Fig. 2D
). These results are consistent with sDll4-initiated Notch pathway activation, but enforced constitutive activation of the Notch1 pathway has a more profound inhibitory effect on cell proliferation. Taken together, our data demonstrate that activation of the Notch1 pathway inhibits human endothelial cell proliferation in vitro.
Activation of Notch1 signaling represses MAPK and PI3K/Akt pathway signaling in endothelial cells
Since constitutive activation of the Notch1 pathway achieved a more profound suppressive effect on endothelial cell proliferation, we used NIC/lentiviral-transfected stable cell lines in all subsequent attempts to identify the signaling mechanism. To determine the intracellular signaling pathways that mediate Notchs effect on cell proliferation inhibition, we tested the potential of activated Notch1 to regulate 2 proliferation-related signal transduction pathwaysthe MAPK and PI3K/Akt pathways. Both pathways are activated following vascular endothelial growth factor (VEGF) or serum stimulation in HIAECs (28)
and HMVECs (13
, 37)
. In HIAECs expressing NIC, phosphorylation of Akt 30 min after mitogen stimulation [50 ng/ml of recombinant human VEGF (h-VEGF) or complete M199 medium containing 10% of FBS] was significantly inhibited compared with that in control cells. Similarly, phosphorylation of Erk1/2 (p44/42) 15 min after mitogen stimulation was significantly suppressed (Fig. 3
A). Because activated Notch1 suppresses endothelial cell proliferation but prolongs cell survival (to maintain growth arrest but not induce senescence as growth-arrest is reversible by resupplement of serum) (28)
, HIAEC-NIC cells had basal levels of phosphor-Akt and -Erk1/2 compared with HIAEC-GFP control cells under starvation conditions. In HMVECs, very similar results were observed despite higher basal levels of phosphor-Akt and -Erk1/2 after starvation. To confirm the effects of activation of Notch pathway on regulating MAPK and PI3K/Akt pathway activities by using a more natural Notch activation system, we tested the effect of sJag1 stimulation on the phosphorylation of Erk1/2 and Akt in HMVECs. 1 x 106 HMVECs starved for 20 h in serum-free M199 medium were treated with anti-IgG (2 µg/ml) crosslinked sJag1 or sPTPBR7 (2 µg/ml), respectively, 10 min before reapplying 50 ng/ml of h-VEGF. Phosphorylation of Erk1/2 and Akt 20 min after h-VEGF stimulation was suppressed, though slightly (Fig. 3B
). This is consistent with the weak effect of sJag1 on endothelial cell proliferation, which might reflect the physiological concentration of endogenous Notch1 signaling strength. Thus, activation of Notch1 signaling negatively regulates MAPK and Akt pathways in endothelial cells.
|
MAPK and PI3K/Akt pathways are responsible for mediating activated Notch1-induced cell proliferation inhibition
To investigate whether changes in the activity of the PI3K/Akt pathway account for Notch1-induced cell proliferation control, we introduced either an active mutant of Akt (Myr-Akt) (30)
or GFP (as a control) into HMVEC-NIC cells using adenoviral vectors for gene transfer. Forty-eight hours after adenovirus infection, cells were harvested for subsequent analyses. The Myr-Akttransfected cells showed increased phosphorylation of Akt (Fig. 4
A, upper panel). Cell proliferation assays for HMVEC-NIC demonstrated that their decreased proliferation rate was restored if the Akt activity was enhanced (Fig. 4A
, lower panel).
|
We tested the mediating effect of the MAPK pathway on Notch endothelial cell growth inhibition by transfecting an active mutant of H-RasV12 or HA-tagged B-RAFV600E into HMVEC-NIC cells. We used Western blots to confirm the expression of H-RasV12 and B-RAFV600E as well as the activation of MAPK pathway in transfected cells (Fig. 4B
). Expression of H-RasV12 or B-RAFV600E rescued the decreased proliferation rate of HMVEC-NIC cells, implying that the MAPK pathway, like the PI3K/Akt pathway, is indeed responsible for mediating Notch1 signaling-induced inhibition of endothelial cell proliferation. Similar effects were observed in Myr-Akt- and H-RasV12- or HA-tagged B-RAFV600Etransfected HIAEC-NIC cells (data not shown). Introduction of Myr-Akt or H-RasV12 into HMVEC-GFP control cells also increased their proliferation rates (data not shown). This is not surprising as Akt and Ras are not Notch pathway-specific targets but are general signaling molecules required for cell proliferation/survival. Our study places MAPK and PI3K/Akt pathways under the control of Notch signaling and suggests certain practically useful "Ex-Notch signaling pathway" targets to municipalize Notchs effect. Taken together, our results strongly indicate that Notch1 pathway activation inhibits endothelial cell proliferation by concurrently regulating the MAPK and PI3K/Akt signaling pathways.
Roles of Notch1 signaling in cell proliferation control is transcription-dependent
To further elucidate the mechanism by which Notch pathway activation suppresses PI3K/Akt and MAPK pathway-mediated endothelial cell proliferation, we tested whether the process is transcription-dependent or -independent. Mounting evidence points to a transcription-independent mechanism in mediating multiple effects of Notch signaling (38
, 39)
. We first tested the effect of HES1 on HMVEC cell growth. HES1 is a downstream target molecule of the Notch signaling cascade whose expression depends on NIC/CSL/MAML complex-mediated gene transcription. When introduced into HMVEC with an adenoviral vector (50 pfu/cell), HES1 suppressed cell proliferation relative to GFP-transfected or untreated parental cells (Fig. 5
A). This finding suggests a transcription-dependent mechanism in the execution of Notch signaling. Because MAML is required to transcribe downstream target genes of the Notch pathway, we decided to investigate a potential role of MAML1 in controlling endothelial cell proliferation by introducing a dominant-negative mutant of MAML1/pBabe [MAML1 (a truncated mutant containing amino acid 1305) into HMVEC-NIC cells (DN-MAML1-HMVEC-NIC). We used pBabe as a control (Mock-HMVEC-NIC]. Cells infected with retroviruses at 2 MOI were pooled after 48 h and used for subsequent assays. Expression of DN-MAML1 in cells was demonstrated by Western blotting (Fig. 5B
). As expected, DN-MAML1 partly altered cell proliferation rates induced by activated Notch1 (Fig. 5B
). This result suggests that the effects of Notch signaling on cell proliferation control are mediated, at least partly, by the Notch/MAML-HES cascade and are transcription-dependent.
|
We then examined whether MAML1 is also required for Notch1-mediated vascular network formation. Compared with control cells (pBabe-HMVEC-NIC), constitutive expression of DN-MAML1 in HMVEC-NIC cells retarded their network formation on Matrigel. In pBabe-HMVEC-NIC cells, initial immature network formation started
2 h after seeding cells on Matrigel and matured networks formed after
6 h; whereas in DN-MAML1-HMVEC-NIC cells, fewer networks formed at 6 h (Fig. 5C
). These results indicate that the effects of Notch signaling on endothelial cell network formation are also mediated through the Notch-MAML cascade. Thus, Notch signaling suppresses endothelial cell proliferation while it enhances endothelial cell differentiation. It supports our previous hypothesis that Notch signaling induces a differentiation-associated growth arrest, which is essential to angiogenesis (28)
.
Effect of Notch signaling on controlling MAPK and PI3K/Akt pathways is MAML1-dependent
To address whether the effects of MAML1 on endothelial cell proliferation control are mediated through the MAPK and PI3K/Akt pathways, we examined whether DN-MAML1 could alter NIC-induced MAPK and PI3K/Akt pathway activities. Compared with Mock-HMVEC-NIC control cells, phosphorylation of Erk1/2 following mitogen stimulation (h-VEGF, 50 ng/ml) was significantly re-established in DN-MAML1-HMVEC-NIC cells (Fig. 6
). Similarly, phosphorylation of Akt following mitogen stimulation was also remarkably reversed. Very similar results were obtained in HIAEC-NIC cells (data not shown). These data demonstrate that MAML1 is indeed responsible for mediating the effects of activated Notch signaling on cell proliferation control by regulating the MAPK and PI3K/Akt signaling pathways.
|
DISCUSSION
Endothelial cell proliferation is required for vascular spouting and elongation during new blood vessel formation. When endothelial cells differentiate, which is required for remodeling and maturation of newly formed blood vessels, the cell cycle needs to be arrested. This cessation is known as differentiation-associated cell cycle arrest (40)
. In matured vasculature, most of the endothelial cells remain in a quiescent state. Notch signaling is known to be involved in remodeling newly formed vessels in a temporal and spatial fashion. It has been suggested that Notch signaling is silent during the early stages of angiogenesis (when active endothelial cell proliferation is required) but activated during vessel maturation [when endothelial cells cease proliferation and likely undergo differentiation-associated cell cycle arrest (21
, 41)
]. Notch pathway activation may also be involved in endothelial cell contact inhibition (22)
. If true, this supports the hypothesis that Notch signaling helps control vessel homeostasis by maintaining endothelial cell quiescence (21)
.
The current study suggests that the MAPK and PI3K/Akt pathways are under the control of Notch signaling and that both pathways are responsible for the ultimate outcome of Notch signaling-induced cell proliferation inhibition. Our work establishes a direct link between the pathways of Notch, MAPK, and PI3K/Akt and provides an explanation for the mechanisms of controlling cell growth by Notch signaling in endothelial cells. The signaling cascades delivered from both MAPK and PI3K/Akt pathways regulate cell cycle machinery. It has been demonstrated in endothelial cells that Notch signaling inhibits phosphorylation of Rb (12)
and mitogen-induced up-regulation of p21Cip1 (22)
. Our findings may well bridge the gap between Notch activation and negative regulation of cell cycle machinery.
Depending on cell type and context, the Notch pathway can generate either inhibitory or proliferative signals (42
, 43)
. Very similar to its role in endothelial cells, Notch signaling also inhibits keratinocyte proliferation by inducing p21Cip1 (44)
and induces cell growth arrest in small cell lung cancer (32)
, prostate cancer (45)
, and hepatocellular carcinoma (46)
, which is associated with a cell cycle block at G1. In contrast, activation of the Notch pathway induces ectopic T cell proliferation in bone marrow (47)
and provides cell proliferation cues in acute lymphoblastic T cell leukemia (48)
, mouse mammary tumors (9)
, and transformed kidney epithelial cells (49)
. It is unclear whether suppression or promotion of cell proliferation by Notch signaling in other cell types occurs by inhibiting or activating the MAPK and PI3K/Akt pathways. It would be interesting to test this possibility.
Classical Notch signaling is transmitted by means of the Notch-NIC/CSL/MAML cascade. Recent evidence suggests that a transcription-independent mechanism exists for mediating the multiple effects of Notch signaling (38
, 39)
. It is likely that Notch signaling regulates the MAPK and PI3K/Akt pathways at the post-transcriptional concentration because (a) HES1, a post-transcriptional target gene product, can mimic the effect of Notch on endothelial cell proliferation control; and (b) MAML1 is an essential element for initiating transcription. DN-MAML1 can antagonize the effect of Notch on MAPK- and PI3K/Akt pathway-mediated cellular proliferative or inhibitory signals. Consistently, our preliminary efforts in detecting a direct association between NIC and MAPK or Akt by coimmunoprecipitation were unsuccessful (data not shown). This supports the notion that intracellular Notch itself does not directly regulate the MAPK and PI3K/Akt pathways. Because MAPK and PI3K/Akt pathways are simultaneously controlled by the Notch/MAML-HES cascade, and these 2 parallel pathways are initiated by receptor tyrosine kinases/phosphatases or adaptor-mediated kinases/phosphatases, it is more likely that regulation of the MAPK and PI3K/Akt pathways by the Notch/MAML-HES cascade is mediated by regulating common kinases/phosphatases. It has been reported that Notch activation down-regulates VEGF-R2 expression on endothelial cells (41)
. Decreased expression of VEGF-R2 is likely responsible for initiating weak MAPK and PI3K/Akt pathway activation (considering that VEGF stimulation was used in our experiments). However, since complete M199 medium and VEGF achieve similar effects, VEGF-R2 is obviously not the only target molecule to mediate Notchs suppression. Future studies to identify such Notch signaling-induced target molecules will help define the mechanism underlying the crosstalk between Notch signaling and the MAPK and PI3K/Akt pathways.
ACKNOWLEDGMENTS
We thank J. M. Wilson for providing the GFP lentiviral vector; D. W. Ball and W. Ogawa for providing recombinant adenoviruses; D. Tuveson and G. Robertson for H-RasV12/pBabe-puro and HA-tagged B-RafV600E/pBabe plasmids; T. Kadesch for Notch1 genes and sJag1; S. Kusano for Dll4/pcDNA3; T. Sudo for anti-HES1 Ab; and G. P. Nalon for the Phoenix cell line. We also thank G. Ascione for preparing the manuscript. This work was supported by grants from the National Institutes of Health (CA47159, CA76674, CA25874, and CA10815) and partially supported by funds from the Commonwealth Universal Research Enhancement Program, PA Department of Health.
REFERENCES
Vß3 integrin synergistically rescue angiogenesis via N-Ras and PI3-K signaling in human microvascular endothelial cells. FASEB J. 17,1931-1933This article has been cited by other articles:
![]() |
M. R. Swift and B. M. Weinstein Arterial-Venous Specification During Development Circ. Res., March 13, 2009; 104(5): 576 - 588. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Ghaleb, G. Aggarwal, A. B. Bialkowska, M. O. Nandan, and V. W. Yang Notch Inhibits Expression of the Kruppel-Like Factor 4 Tumor Suppressor in the Intestinal Epithelium Mol. Cancer Res., December 1, 2008; 6(12): 1920 - 1927. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Segarra, C. K. Williams, M. d. l. L. Sierra, M. Bernardo, P. J. McCormick, D. Maric, C. Regino, P. Choyke, and G. Tosato Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth Blood, September 1, 2008; 112(5): 1904 - 1911. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-R. Dou, Y.-C. Wang, X.-B. Hu, L.-H. Hou, C.-M. Wang, J.-F. Xu, Y.-S. Wang, Y.-M. Liang, L.-B. Yao, A.-G. Yang, et al. RBP-J, the transcription factor downstream of Notch receptors, is essential for the maintenance of vascular homeostasis in adult mice FASEB J, May 1, 2008; 22(5): 1606 - 1617. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wu, Q. Zhou, L. Huang, A. Sun, K. Wang, Y. Zou, and J. Ge Ageing-exaggerated proliferation of vascular smooth muscle cells is related to attenuation of Jagged1 expression in endothelial cells Cardiovasc Res, March 1, 2008; 77(4): 800 - 808. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kunnimalaiyaan and H. Chen Tumor Suppressor Role of Notch-1 Signaling in Neuroendocrine Tumors Oncologist, May 1, 2007; 12(5): 535 - 542. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Leslie, L. Ariza-McNaughton, A. L. Bermange, R. McAdow, S. L. Johnson, and J. Lewis Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis Development, March 1, 2007; 134(5): 839 - 844. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Lamont and S. Childs MAPping Out Arteries and Veins Sci. Signal., October 3, 2006; 2006(355): pe39 - pe39. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |